Table I.
lncRNA | Expression in glioma | Maintenance of growth signals | Resistance to growth inhibition signals | Resistance to apoptosis | Ability to replicate indefinitely | Angiogenesis | Invasion | Reprogramming of energy metabolism | Evading immune cell attack | (Refs.) |
---|---|---|---|---|---|---|---|---|---|---|
H19 | ↑ | + | + | + | + | (21,52,69, 72,73,91) | ||||
XIST | ↑ | + | (23,24) | |||||||
HOXD-AS1 | ↑ | + | + | (25) | ||||||
CCAT1 | ↑ | + | + | + | (26) | |||||
LOC728196 | ↑ | + | + | (27) | ||||||
PLAC2 | ↓ | – | (31) | |||||||
PTENP1 | ↓ | – | (32) | |||||||
HOXA11-AS | ↑ | + | + | + | + | (33,76) | ||||
Plncrna-1 | ↑ | + | + | + | (34–37) | |||||
ADAMTS9-AS2 | ↓ | – | (38) | |||||||
CASC2 | ↑ | + | + | (39) | ||||||
ANRIL | ↑ | + | (41) | |||||||
SNHG3/6/16/2O | ↑ | + | + | (47–50) | ||||||
TUG1 | ↓ | – | – | (51,82) | ||||||
CASC7 | ↓ | – | – | (53) | ||||||
GHET1 | ↑ | + | + | (54) | ||||||
MALAT1 | ↑ | + | + | (56,57) | ||||||
FOXD2-AS1 | ↑ | + | + | + | (59–61) | |||||
TUG1 | ↑ | + | (62) | |||||||
PVT1 | ↑ | + | + | + | (64–66,93) | |||||
AB073614 | ↑ | + | + | (67,68) | ||||||
TSLC1-AS1 | ↓ | – | – | (69) | ||||||
DANCR | ↑ | + | + | (71,75) | ||||||
CCND2-AS1 | ↑ | + | (72) | |||||||
UCA | ↑ | + | + | + | (78) | |||||
TP53TG1 | ↑ | + | (79) | |||||||
LINC00152 | ↑ | + | + | + | (82,89) | |||||
PGM5-AS1 | ↑ | + | (83) | |||||||
ST20-AS1 | ↑ | + | (83) | |||||||
AGAP2-AS1 | ↑ | + | (83) | |||||||
MIR155HG | ↑ | + | (83) | |||||||
SNHG8 | ↓ | – | (83) | |||||||
LINC00937 | ↓ | – | (83) | |||||||
MAPKAPK5-AS1 | ↓ | – | (83) | |||||||
HCG18 | ↓ | – | (83) |
↑, increased expression; ↓, decreased expression; +, promoting effect; −, inhibitory effect; lncRNA, long non-coding RNA.